However, two major issues should not be overlooked, namely, the resistance to immunotherapy or the short-lived response to immunotherapy against PD-1/PD-L1 in many patients, the main reason for which is the tumor’s escape from the host’s immune surveillance [2]. Here, PDCD1 is linked to neoplasm.